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Cancers such as acute lymphoblastic leukemia 
(ALL) and acute myeloid leukemia (AML) attack 
and incapacitate blood generating cells in the bone 
marrow. Therefore, bone marrow transplantation 
becomes indispensable for patients with ALL and 
AML. However, after the bone marrow transplanta-
tion procedure, the immune system of the recipient 
could reject the donor’s bone marrow. Thus, before 
the transplantation operation is executed, a con-
ditioning regimen is prescribed to bone marrow 
recipients. The regimen is normally aimed at creat-
ing space for new bone marrow and also eliminates 
malignant cells, since they are radiosensitive [1]. In 
other terms, the conditioning regimen is an immu-
nosuppression procedure [1]. The regimen could be 
implemented solely with chemotherapy (drugs), or 
in conjunction with radiation therapy, in the form 
of total body irradiation (TBI). 
AbstrAct
background: The dosimetric characterization of volumetric modulated arc therapy (VMaT)-based total-body irradiation (TBI) 
in pediatric patients is evaluated. 
Materials and methods: Twenty-two patients between the ages of 2 and 12 years were enrolled for VMaT-based TBI from 
2018 to 2020. Three isocenters were irradiated over three overlapping arcs. While prescribing 90% of the TBI dose to the plan-
ning treatment volume (pTV), two fractions (2 Gy each) were delivered each day; hence 12 Gy was delivered in six fractions. 
During treatment optimization, the mean lung and kidney doses were set not to exceed 7 Gy and 7.5 Gy, respectively. The 
maximum lens dose was also set to less than 4 Gy. patient quality assurance was carried out by comparing treatment planning 
system doses to the 3-dimensional measured doses by the arcchecK® detector. The electronic portal imaging device (epID) 
gamma indices were also obtained.
results: The average mean lung dose was 7.75 ± 0.18 Gy, mean kidney dose 7.63 ± 0.26 Gy, maximum lens dose 4.41 ± 0.39 Gy, 
and the mean pTV dose 12.69 ± 0.16 Gy. The average pTV heterogeneity index was 1.15 ± 0.03. average differences in mean 
kidney dose, mean lung dose, and mean target dose were 2.79% ± 0.88, 0.84% ± 0.45 and 0.93% ± 0.47, respectively; when 
comparing planned and arcchecK® measured doses. Only grade 1–2 radiation toxicities were recorded, based on cTcae v5.0 
scoring criteria. 
conclusions: VMaT-TBI was characterized with good pTV coverage, homogeneous dose distribution, planned and measured 
dose agreement, and low toxicity.
Key words: toxicity; homogeneity; medical dosimetry; organs at risk (Oars); planned target volume (pTV)
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During TBI, the planned target volume (PTV) 
is the whole body. In this case, the dose delivered 
to the whole body (PTV) should be sufficient 
to achieve the goals of the plan, but also spare 
the organs at risk (OARs). Particularly, during 
TBI, the OARs mostly include the lungs, kidneys, 
the liver and pre-irradiated regions [2, 3]. Even 
with execution of optimum PTVs, TBI is associ-
ated with side effects including tiredness, nausea 
and vomiting, cataracts, skin redness, infertility 
in both men and women, hair loss, diarrhea, and 
even induction of secondary cancers. Owing to 
the those side effects, dose heterogeneities, tox-
icities, and secondary malignancies [4], there has 
been a significant decline in the TBI-based condi-
tioning regimens [5]. 
Classical TBI is associated with shortcom-
ings, such as longer treatment delivery times and 
higher toxicity levels, in the form of delivering 
non-sparing doses to OARs (in both pediatric 
and adult patients) [6, 7]. Diverging from the 
30-year-old conventional TBI execution tech-
niques that employ non-conformal large opposed 
whole-body fields [2], current methods have re-
sorted to implementing targeted TBI in the form 
of total marrow irradiation (TMI) [1]. TMI has 
been achieved using image-guided intensity mod-
ulated radiation therapy (IG-IMRT) [1]. Other 
studies have exploited volumetric modulated arc 
therapy (VMAT) for delivery of TMI [1, 3, 8, 9]. 
This VMAT technique has been implemented in 
order to reduce organ doses and toxicities, and 
also improve dose uniformity [1]. During TMI 
treatment planning, 3–4 isocenters cover the tar-
get organs and the treatment is delivered in mul-
tiple dynamic IMRT arcs [1].
However, limited studies have reported the eval-
uation of the radiation doses and toxicities/mor-
bidities associated with VMAT-based TMI/TBI in 
pediatric patients. Moreover, most clinical TMI tri-
als recently done are pilot or phase one trials [1]. 
Furthermore, as observed in various studies [8, 10, 
11], pediatric and adult patients are prescribed the 
same dose, i.e., a total of 12 Gy (2 Gy per fraction), 
during treatment delivery. However, radiation ex-
posure to pediatric patients should be stringent 
because they still have a longer lifespan to live. 
For instance, growth disturbances were reported in 
prepubertal pediatric patients, where two treated 
patients, identical twins, lost 8% of their height [6]. 
Owing to TBI related radiation exposures, children 
are at a high risk of developing multiple endocrine 
disorders [12]. For those reasons, in some clin-
ics, cutting-edge and precise techniques employing 
proton therapy are reserved for/priority is given to 
pediatric patients.
Whereas studies have demonstrated VMAT 
could be a feasible technique for delivering TBI 
[13, 14], limited focus has been directed towards 
the implications and dosimetric characterization of 
VMAT-based TBI in pediatric patients.
In this investigation, VMAT plans are formu-
lated in the treatment planning system (TPS) and 
executed using a linear accelerator, following the 
normal clinical workflow. While patient-specific 
quality assurance (QA) is carried out using the Arc-
CHECK® detector array and the electronic portal 
imaging device (EPID), the toxicity score is evalu-
ated according to the Common Terminology Crite-
ria for Adverse Events (CTCAE v5.0).
This study, therefore, aims at evaluating the ap-
propriateness of VMAT-based TBI for pediatric 
patients, by elaborating the dosimetric character-




Pediatric patients in this study were stem-cell 
transplant candidates who received TBI treatment 
from our oncology hospital. Twenty-two patients at 
the ages of 2 to 12 years were enrolled into the study 
from 2018 to 2020. Four were female, whereas 18 
were male. 
patient positioning during computed 
tomography (cT)
The patients were laid on the patient couch of 
a Siemens (SOMATOM Emotion™, Erlangen, Ger-
many) CT scanner in a supine position. For immo-
bilization, a vacuum positioning cushion (CIVCO® 
Radiotherapy Vac-Lok™ & Positioning Cushions, 
Auckland, New Zealand) was additionally placed 
on the patient couch. 
contouring
The Varian Eclipse SomaVision (Varian Medi-
cal Systems, Palo Alto, CA) software interface was 
employed for contouring. Each CT slice was 3 mm. 
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The contoured organs included lungs, kidneys, and 
lens. The PTV comprised the whole body, and a 2 
mm margin was allowed between the PTV and the 
skin.
Treatment planning and dose 
prescription 
The VMAT plans implemented for TBI in this 
study were created using the Varian TrueBeam v2.5 
linear accelerator (Varian Medical Systems, Palo 
Alto, CA). This linac is equipped with a Varian 
Millenium 120-leaf multi-leaf collimator system 
(MLC) (Varian Medical Systems, Palo Alto, CA). 
At a nominal skin-axis distance (SAD) of 100 cm, 
the maximum field size was 40 × 40 cm2, and MLC 
minimum leaf-width is 5 mm.
The Eclipse™ TPS version 13.6 (Varian Medi-
cal Systems, Palo Alto, CA) was used to formulate 
dual-arc VMAT plans implemented here for TBI 
while executing the anisotropic analytical algo-
rithm (AAA) 13.6.23 calculation configuration. The 
nominal variable dose rate was set to acquire a dose 
rate of 600 MU/min in the 50–600 MU/min range.
During treatment planning optimization, 90% 
of the PTV was prescribed a total dose of 12 Gy 
in six fractions. Two fractions (2 Gy each) were 
delivered to patients on three consecutive days. 
A time delay of at least six hours was observed be-
tween the fractions. The mean doses to the lungs 
and kidneys were set to be less than 7 Gy and 
7.5 Gy, respectively. The maximum lens dose was 
also set to be less than 4 Gy. In the present study, 
we defined the heterogeneity index (HI) as the 
ratio of D5 to D95, where D5 and D95 are the 
minimum doses encompassing 5% and 95% of the 
PTV, respectively. 
The linac executed these plans using the 6 MV 
photon energy setting. This linac’s Varian On-Board 
Imager™ (OBI) kilovoltage imaging system ascer-
tained the patient positioning preceding irradia-
tions.
patient set-up verification 
Patient set-up was verified by kV cone-beam CT 
(CBCT) imaging (TrueBeam v2.5) incorporated in 
the linac’s system, in the form of image-guided RT 
(IGRT) for the VMAT-TBI. 
The average beamon time for each patient was 
30 ± 5 minutes, whereas the average patient set-up 
and positioning time was 20 minutes.  
Quality assurance
The pre-treatment VMAT-based plans for all the 
patients enrolled in this study were verified using 
the ArcCHECK® (Sun Nuclear: Melbourne, FL, 
USA) four-dimensional (4-D) detector array and 
the EPID. The ArcCHECK® array system is in the 
form of a cylinder with a diameter of 21 cm which 
constitutes 1,386 SunPoint Diode detectors in a he-
lical grid geometry (1 cm offset). This ArcCHECK® 
device’s array detector spacing is 1 cm and it also 
consists of acrylic phantom material. The device was 
placed on the treatment couch as per the positioning 
guidelines in the product manual (one side facing 
the gantry). A field size of 10 cm × 10 cm was set 
up on the detector array matrix. We calculated the 
percentage dose differences between the planned 
and measured mean kidney dose, mean lung dose, 
and mean PTV dose using the ArcCHECK® system.
Furthermore, before treatment delivery, addi-
tional treatment plan verification in the form of 
EPID-based gamma indices was executed. For each 
patient, the average of the gamma indices from each 
PTV was computed and tabulated.
Treatment plan settings 
and optimization
As in similar studies [1, 8], the dose delivery was 
implemented using three isocenters with dual arcs. 
The arc angles were clockwise from 181° to 179°, 
and counterclockwise from 179° to 181°. The over-
lapping regions of the arcs were up to 2 cm and were 
taken into account by the treatment planning sys-
tem, in order to avoid double dose in the junction 
regions. Isocenter positions were automatically set 
along the patient’s longitudinal axis by the Eclipse 
TPS, observed as red dots in Figure 1A. Each arc 
was irradiated using one isocenter, as shown in 
Figure 1B. The three arcs were consecutively irradi-
ated while the treatment couch was longitudinally 
translated. During the execution of each arc, the 
collimator was also rotated to 10°.
Anatomic structures were automatically con-
toured using Varian’s comprehensive automatic 
and semi-automatic contouring tools software 
—  Varian Eclipse SomaVision. The automatically 
contoured structures were checked and manually 
corrected/adjusted if necessary. On average, con-
touring, planning and optimization required ap-
proximately 6 hours. This time includes discussions 
and evaluations by the oncologists and physicists.
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Toxicity evaluation
Investigation into the level of toxicity associated 
with the treatments was evaluated while referencing 
the CTCAE v5.0. 
results
Dose distribution and patient Qa 
A summary of the three-dimensional (3D) dose 
distributions in the lungs, clinical target volume 
(CTV), and PTV are graphically represented in the 
form of a dose volume histogram (DVH) in Figure 2. 
Upon planned and ArcCHECK® system measured 
dose calculations, we obtained average differences of 
0.84% ± 0.45, 2.79% ± 0.88, and 0.93% ± 0.47 in the 
mean lung, mean kidney, and mean PTV doses, 
respectively, as elaborated in Table 1.
Also, the mean EPID average PTV gamma index 
across all the 22 patients was 0.37 with a standard 
deviation of 0.028, as observed in Table 1. 
Dosimetric characterization
Among the 22 pediatric patients enrolled in 
this study, the average mean lung and kidney 
a B




















Figure 2. Dose volume histogram: yellow — lungs, inner red — planned target volume (pTV) — pTV, and outer red — clinical 
target volume (cTV)
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doses were 7.75 Gy and 7.63 Gy, respectively. On 
the other hand, the average for the maximum 
lens dose and mean PTV dose were also 4.41 and 
12.66 Gy, respectively. The maximum lens dose 
was characterized with the highest percentage er-
ror in dose (8.80%) whereas the PTV mean dose 
had the lowest percentage error (1.27%), as can 
be observed in Table 2. Furthermore in Table 2, 
the average heterogeneity index (HI) of the PTV 
for all the 22 cases was 1.15 ± 0.03 and the aver-
age dose covering 95% of the target (D95) was 
also 11.4 Gy.
During treatment planning, the dose distribution 
attained by the TPS in the transverse, coronal and 
sagittal planes is illustrated in Figure 3. Upon execu-
tion of the treatment plans on the patients, the mean 
follow-up time of all the patients was 9 months. 
When our VMAT-TBI plans were recalculated 
with a 5-mm misalignment, on average; 4.0% ± 1.6 
higher lung mean dose, 9.9% ± 3.1 higher lung 
max. dose, and 12.3% ± 1.9 higher PTV max. dose 
was attained. On the other hand, recalculation 
with a 10-mm misalignment resulted in higher 
lung mean, lung max., and PTV max. doses which 
were on average; 6.2% ± 1.7, 15.0% ± 3.8, and 
18.8% ± 2.7 higher, respectively — as illustrated 
in Table 3.
Toxicities and morbidities
Radiation-related acute morbidities were evalu-
ated while referring to the CTCAE v5.0 toxicity 
evaluation protocol. In this study, all the toxicities 
were of Grade 1–2, and no Grade 3–4 toxicities 
were reported. As demonstrated by Table 4, the 
most recurrent morbidity across the investigated 
patient population was patch mucositis with a rate 
of 50%. Conversely, the least recurrent morbidity 
was faint/dull erythema (5%).
table 1. arcchecK®-based dose differences and average planned target volume (pTV) g-index per patient
Patient Number 
(#)
Mean lung dose 
difference (%)
Mean kidney dose 
difference (%)
Mean PTV dose  
difference (%)
EPID Average  
PTV g-index 
1 0.7 2.4 0.6 0.39
2 0.4 3.3 0.5 0.34
3 0.3 1.7 0.6 0.38
4 1.3 3.6 0.3 0.37
5 0.2 1.9 1.1 0.41
6 0.7 2.3 1.9 0.36
7 1.1 2.6 0.6 0.33
8 0.8 3.9 1.4 0.41
9 0.6 2.2 0.8 0.35
10 0.4 2.8 0.8 0.36
11 1.1 2.0 1.2 0.37
12 1.5 1.7 1.6 0.36
13 0.5 3.1 0.9 0.33
14 0.6 4.2 0.4 0.42
15 1.7 2.8 1.0 0.39
16 1.3 1.3 1.3 0.34
17 0.2 2.2 0.6 0.32
18 0.5 2.9 1.7 0.38
19 0.8 2.4 0.5 0.36
20 1.4 4.5 0.3 0.34
21 1.3 2.7 1.4 0.40
22 1.1 4.1 0.9 0.37
Mean ± sD 0.84 ± 0.45 2.79 ± 0.88 0.93 ± 0.47 0.37 ± 0.028
sD — standard deviation
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Discussion
Linac-based VMAT-TBI has been adopted in 
numerous studies [3, 8, 10] owing to some of its 
advantages, including the highly accurate on-board 
positioning and intra-fraction motion detecting 
mechanisms employing kV CBCT and optical sur-
face-guided therapy [8]: when compared to heli-
cal tomotherapy (HT) and classical TBI. Because 
secondary malignancies are more prevalent in the 
0–10 years age group [15], the benefits of imple-
menting different VMAT-TBI techniques could be 
manipulated to offer better treatment optimization 
and organ sparing in pediatric patients.
In recent work by Blomain and colleagues [10], 
VMAT-TBI pediatric patient plans demonstrated 
improved gonadal sparing in comparison to simu-
lated two-dimensional (2D) conventional plans. 
For instance, while the global testes D max. is 2.35 
Gy (117.5%), Blomain et al. [10] reported an im-
proved VMAT-TBI PTV coverage of 2 Gy D90%, 
yet that of the conventional 2D anterior-posteri-
or/posterior-anterior (AP-PA) plans was 1.9 Gy 
D90% [10]. Following the standard conditioning 
therapy in almost all allogeneic transplantation 
centers worldwide, our conditioning regimen im-
plemented a planned total dose of 12 Gy because 
the transplants were from related donors [3]. Simi-
table 2. VMaT-based TBI planning parameters and dosimetric coverage


























1 2 6 12 7.82 7.14 3.66 12.63 11.4 1.11
2 2 6 12 7.72 7.24 3.99 12.55 11.5 1.12
3 2 6 12 7.21 7.16 3.83 12.43 11.4 1.13
4 2 6 12 7.72 7.91 3.96 12.77 11.5 1.16
5 2 6 12 7.88 7.94 4.53 12.64 11.5 1.18
6 2 6 12 7.91 7.56 4.79 12.93 11.3 1.22
7 2 6 12 7.68 7.62 4.88 12.51 11.3 1.13
8 2 6 12 7.93 7.82 4.01 12.41 11.4 1.11
9 2 6 12 7.69 7.91 4.39 12.75 11.5 1.15
10 2 6 12 7.82 7.96 3.94 12.53 11.5 1.11
11 2 6 12 7.65 7.72 4.53 12.71 11.3 1.14
12 2 6 12 7.83 7.93 4.72 12.86 11.5 1.16
13 2 6 12 7.55 7.63 4.11 12.63 11.4 1.14
14 2 6 12 7.92 7.49 4.92 12.83 11.5 1.15
15 2 6 12 7.78 7.71 4.16 12.92 11.3 1.16
16 2 6 12 7.58 7.33 4.61 12.76 11.4 1.17
17 2 6 12 7.93 7.72 4.41 12.58 11.3 1.12
18 2 6 12 7.95 7.88 4.81 12.97 11.5 1.21
19 2 6 12 7.86 7.68 4.61 12.61 11.4 1.16
20 2 6 12 7.79 7.51 4.91 12.88 11.3 1.17
21 2 6 12 7.42 7.38 4.74 12.62 11.5 1.12
22 2 6 12 7.76 7.55 4.44 12.66 11.4 1.21
average 7.75 7.63 4.41 12.69 11.41 1.15
error 0.18 0.26 0.39 0.16 0.08 0.03
% error 2.35 3.37 8.80 1.27 0.73 2.61
range 7.21–7.95 7.14–7.96 3.66–4.92 12.41–12.97 11.3–11.5 1.11–1.22
pTV — planned target volume, hI — heterogeneity index
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lar to the work by Blomain et al. [10], our pediatric 
VMAT-TBI favorably achieved an 11.4 Gy D95% 
PTV coverage. 
With an age group of 4–22 years, Gruen’s group 
[11] demonstrated HT-TBI as a feasible, well tol-
erated, and beneficial tool with regard to dose 
distribution (homogeneity) and reducing doses to 
OARs. Upon comparison, our mean lung dose was 
7.75 Gy, which was less than that (9.14 Gy) of Gru-
en’s group [11]. That was because the patient age 
group in Gruen’s group [11] was from 4–22 years 
(10 years wider than ours), which implied a larger 
lung volume, hence a higher mean lung dose. Fur-
Figure 3. VMaT-based TBI dose distribution in the (A) coronal, (b) sagittal and (c) transverse planes
a B
c D
ther, in another study implementing VMAT-TBI 
[8], a broader age group from 6–63 years-old (im-
plying a larger lung volume) was treated; hence 
a higher mean lung dose of 9.7 Gy. Therefore, 
in order to facilitate comparison of OAR pediat-
ric doses from different clinics worldwide, more 
studies have to be carried out implementing the 
same pediatric age group and different VMAT-TBI 
techniques. Ultimately, a more feasible technique 
providing better organ sparing doses, while simul-
taneously achieving the core objectives of TBI, 
could be attained for pediatric patients. In other 
terms, one technique could consequently illustrate 
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a better dosimetric characterization for TBI in 
pediatric patients. 
Excluding intentionally shielded or boosted 
regions, achievement of relative dose homoge-
neity throughout the body is one of the core 
objectives in TBI [16]. Similar to elsewhere [8, 
17, 18], we defined HI as D5/D95 in the present 
study. A lower HI value (closer to 1) would im-
ply a better dose homogeneity [18]. In our study 
we reported an average HI value of 1.15 with 
a standard deviation of 0.03 which, therefore, 
represents a homogeneous dose distribution in 
all the patient plans. 
Studies exploiting VMAT-TBI have executed 
various dose verification methods and devices, in-
cluding ionization chambers [11], films [19], ther-
moluminescent detectors (TLDs) [11], and opti-
cally stimulated luminescent dosimeters (OSLs) 
[10]. Nevertheless, all these methods hardly cover 










Loss of appetite 3 14
Xerostomia 2 9
Neck pain 2 9
erythema 1 5
Toxicity scoring was executed as per cTcae v5.0, and no Grade 3–4 toxicities 
were recorded
table 3. Deviation of longitudinal misalignment




















1 4.7 9.3 12.9 6.1 16.8 16.2
2 3.8 9.9 13.6 8.3 19.8 15.9
3 4.5 12.7 14.3 7.1 12.1 19.8
4 3.6 6.7 11.5 4.8 11 18.7
5 4 14.1 12.9 3.9 10.3 21.1
6 9.5 14.5 11.8 4.1 11.4 19.2
7 2.9 8.8 13.2 6.4 16.2 20.6
8 4.4 11.5 8.9 5.1 20.7 16.4
9 3.5 7.6 10.5 3.9 16.7 19.3
10 5 14.5 12.9 6.6 20.1 17.9
11 1.4 11.3 11.1 8.4 14.2 22.6
12 4.4 14.9 10.3 9.2 12.9 25.3
13 3.1 6.9 13.1 4.1 18.3 16.3
14 4.2 9.5 14.1 7.6 11.9 19
15 4.7 8.8 11.3 7.2 13.1 17.6
16 1.7 5.2 11.9 6.8 8.8 14.4
17 4.4 7.9 16.2 3.6 16.7 20.1
18 2.6 9.5 13.9 6.6 13.9 16.8
19 3.6 7.6 14.2 5.2 23.1 15.9
20 5.2 4.2 10.9 6.1 16.8 16.4
21 4.8 9.9 12.7 7.9 11.3 22.3
22 2.6 13.2 7.9 8.1 13.4 21.3
Mean ± sD 4.0 ± 1.6 9.9 ± 3.1 12.3 ± 1.9 6.2 ± 1.7 15.0 ± 3.8 18.8 ± 2.7
pTV — planned target volume; sD — standard deviation
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the whole of the comparatively large PTV sizes 
associated with TBI. Furthermore, they offer 2D 
dose distributions, yet 3D dose distribution calcu-
lations are necessary to facilitate more accurate QA 
results. That said, we examined dose distributions 
using the ArcCHECK® 4D detector array with a cy-
lindrical geometry that is designed specifically for 
rotational delivery. Hence, we executed 3D patient 
QA by calculating the dose differences between the 
planned and measured mean doses for the lungs, 
kidneys and PTV. 
The EPID is fundamentally a visualization and 
patient set-up monitoring system. However, stud-
ies have also presented amorphous silicon (aSi) 
EPIDs as potential detectors and dosimeters [20]. 
Applying the EPID in a dosimeter mode involves 
comparison between a calculated fluence map 
(predicted dose by the TPS) and the real fluency 
map (measured by the EPID). A gamma analysis 
tool is used to indicate the calculated-measured 
dose difference relative to acceptance tolerances 
[21]. For the 3%–3mm analysis, the EPID average 
PTV g-index for all the patients was 0.37; that was 
lower than  that (0.39) reported in Tas et al. [8]. In 
agreement, elsewhere, an EPID-based pre-treat-
ment IMRT verification technique was also dem-
onstrated as a good quality assurance (QA) proce-
dure [20]. Therefore, patient quality assurance was 
successfully implemented in this study.
Pertaining to toxicity and follow-up, as report-
ed by Wong et al. [2] from Keane et al. [22], the 
most prevalent toxic effect associated with single 
large-dose TBI of 8–10 Gy is radiation-induced 
interstitial pneumonitis, occurring at a 50% rate 
of which 50% of the cases are fatal. In our study, 
the alternative VMAT-TBI implemented for pe-
diatric patients was associated with mucositis, 
which occurred in 50% of the patients in this 
study. All the acute toxicities reported here were 
transient and manageable, as suggested by Wong 
et al. [2]. Even though children are at a higher 
risk of developing radiation-induced multiple 
endocrine disorders [12, 23], the VMAT-TBI in 
our study did not induce any of such disorders; as 
observed during the 9-month follow-up period. 
Also, similar to the study by Gruen et al. [11], we 
did not record any grade 3–4 toxicities. Hence, 
the VMAT-TBI suggested here is a promising 
and less toxic alternative TBI tool for pediatric 
patients. 
conclusions
In our study, we investigated the application of 
the VMAT-based TBI conditioning regimen in 
22 pediatric patients in the 2–12 years age group. 
VMAT-based TBI has been presented with feasible 
dosimetric values in pediatric patients. We obtained 
a good PTV dose coverage (D95), a low heteroge-
neity index (homogeneous dose distribution), and 
the planned TPS doses agreed to those measured by 
the detector array. After delivery of VMAT-TBI to 
our pediatric patients, as per the CTCAE v5.0, no 
grade 3–4 toxicities were observed; only grade 1–2 
toxicities were reported. Hence, VMAT-TBI has 
been presented with a potential of delivering opti-
mum doses to the PTV (whole body) while sparing 
the sparing OARs in pediatric patients. In the pres-
ent study, we exploited the dual-arc VMAT-TBI. 
However, other VMAT-TBI dosimetric character-
izations in pediatric patients could be explored us-
ing other VMAT techniques such as single-arc and 
2-field VMAT for each isocenter.
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